MDPI Contact

MDPI AG
St. Alban-Anlage 66,
4052 Basel, Switzerland
Support contact
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18

For more contact information, see here.

Advanced Search

You can use * to search for partial matches.

Search Results

3 articles matched your search query. Search Parameters:
Authors = Mayumi Nagashimada

Matches by word:

MAYUMI (26) , NAGASHIMADA (3)

View options
order results:
result details:
results per page:
Articles per page View Sort by
Displaying article 1-50 on page 1 of 1.
Export citation of selected articles as:
Open AccessReply Reply to the Letter to the Editor by Li et al.: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E
Int. J. Mol. Sci. 2017, 18(5), 994; doi:10.3390/ijms18050994
Received: 28 April 2017 / Revised: 28 April 2017 / Accepted: 28 April 2017 / Published: 5 May 2017
Viewed by 354 | PDF Full-text (128 KB) | HTML Full-text | XML Full-text
Open AccessArticle Hepatic Transcriptome Profiles of Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E
Int. J. Mol. Sci. 2017, 18(3), 593; doi:10.3390/ijms18030593
Received: 19 January 2017 / Accepted: 4 March 2017 / Published: 8 March 2017
Cited by 2 | Viewed by 578 | PDF Full-text (2768 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Astaxanthin alleviates hepatic lipid accumulation and peroxidation, inflammation, and fibrosis in mice with high-cholesterol, high-cholate, and high-fat (CL) diet-induced nonalcoholic steatohepatitis (NASH) [...] Full article
(This article belongs to the Special Issue Nutrigenomics of Risk Factors for Disease)
Figures

Open AccessReview Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis
Nutrients 2016, 8(7), 391; doi:10.3390/nu8070391
Received: 25 April 2016 / Revised: 15 June 2016 / Accepted: 22 June 2016 / Published: 24 June 2016
Cited by 5 | Viewed by 1556 | PDF Full-text (1921 KB) | HTML Full-text | XML Full-text
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. It is characterized by a wide spectrum of hepatic changes, which may progress to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is considered a hepatic manifestation of metabolic syndrome; however, mechanisms underlying
[...] Read more.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. It is characterized by a wide spectrum of hepatic changes, which may progress to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is considered a hepatic manifestation of metabolic syndrome; however, mechanisms underlying the onset and progression of NAFLD are still unclear. Resident and recruited macrophages are key players in the homeostatic function of the liver and in the progression of NAFLD to NASH. Progress has been made in understanding the molecular mechanisms underlying the polarized activation of macrophages. New NAFLD therapies will likely involve modification of macrophage polarization by restraining M1 activation or driving M2 activation. Carotenoids are potent antioxidants and anti-inflammatory micronutrients that have been used to prevent and treat NAFLD. In addition to their antioxidative action, carotenoids can regulate macrophage polarization and thereby halt the progression of NASH. In this review, we summarize the molecular mechanisms of macrophage polarization and the function of liver macrophages/Kupffer cells in NAFLD. From our review, we propose that dietary carotenoids, such as β-cryptoxanthin and astaxanthin, be used to prevent or treat NAFLD through the regulation of macrophage polarization and liver homeostasis. Full article

Years

Subjects

Refine Subjects

Journals

Refine Journals

Article Types

Refine Types

Countries

Refine Countries
Back to Top